Biosimilars hold the promise of substantial potential cost savings in health care with no compromise in the efficacy and safety of treatment. Despite this, their adoption in the United States has been ...

Biosimilars are often promoted as cost-saving alternatives to their reference medications. Designed to provide comparable therapeutic efficacy at a reduced price, they have the potential to lower ...

There are now 10 approved biosimilars in the United States, including 3 oncology drugs, and at least 16 others in late-stage development. The introduction of competition into the biologic space ...

Switching from an originator biologic to a biosimilar can sometimes trigger a nocebo effect, where negative expectations lead to worsened symptoms, reduced treatment efficacy, or perceived adverse ...

Please provide your email address to receive an email when new articles are posted on . In October, Boehringer Ingelheim’s adalimumab-adbm secured a landmark FDA approval as the first interchangeable ...